Reappearance of an 11-year-old sequence in an HIV-1 infected patient during treatment interruption

References

• Kijak GH, Simon V, Balfe P, Vanderhoeven J, Pampuro SE, Zala C, et al. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol 2002; 76: 7000–9
   PubMed Web of Science ®Google Scholar
• Chilton D, Dervisevic S, Pillay D, Rider A, Copas A, Miller RF, Edwards SG. Determinants of HIV drug resistance mutations in plasma virus after treatment interruption. AIDS 2005; 19: 2174–5
   PubMed Web of Science ®Google Scholar
• Verhofstede C, Wanzeele FV, van der Gucht B, de Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999; 13: 2541–6
   PubMed Web of Science ®Google Scholar
• Izopet J, Massip P, Souyris C, Sandres K, Puissant B, Obadia M, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000; 14: 2247–55
   PubMed Web of Science ®Google Scholar
• Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D‘Aquila R, et al. Virological and immunological effects of treatment interruption in HIV-1 infected patients with treatment failure. AIDS 2000; 14: 2857–67
   PubMed Web of Science ®Google Scholar
• Walther H, Löw P, Harrer T, Schmitt M, Schwingel E, Tschochner M, et al. No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1 infected individual. JAIDS 2002; 31: 137–46
   Google Scholar
• Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75: 6410–7
   PubMed Web of Science ®Google Scholar
• Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, et al. Persistence of wild type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in paediatric patients with extensive antiretroviral exposure. J Virol 2002; 76: 9481–92
   PubMed Web of Science ®Google Scholar
• Verhofstede C, Noë A, Demecheleer E, de Cabooter N, van Wanzeele F, van der Gucht B, et al. Drug-resistant variants that evolve during non-suppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. JAIDS 2004; 35: 473–83
   Google Scholar
• Lambotte O, Chaix M-L, Gubler B, Nasreddine N, Wallon C, Goujard C, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18: 1147–58
   PubMed Web of Science ®Google Scholar
• Nijhuis M, Boucher CAB, Schipper P, Leitner T, Schuurman R, Albert J. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. PNAS 1998; 95: 14441–6
   PubMed Web of Science ®Google Scholar
• Nijhuis M, Boucher CAB, Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. BioTechniques 1995; 19: 178–82
   PubMed Web of Science ®Google Scholar
• Leitner T, Korovina G, Marquina S, Smolskaya T, Albert J. Molecular epidemiology and MT-2 cell tropism of Russian HIV type 1 variants. AIDS Res Hum Retro 1996; 12: 1595–1603
   PubMed Web of Science ®Google Scholar
• Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13: 2349–59
   PubMed Web of Science ®Google Scholar
• De Jong MD, Veenstra J, Stilianakis NI, Schuurman R, Lange JMA, de Boer R, Boucher CAB. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. PNAS 1996; 93: 5501–6
   PubMed Web of Science ®Google Scholar
• Page, RD, Holmes, EC. Molecular evolution: a phylogenetic approach. Blackwell Science Ltd 1998, OxfordUnited Kingdom.
   Google Scholar
• Parikh, U, Hammond, J, Calef, C, Larder, B, Schinazi, R, Mellors, J. Mutations in retroviral genes associated with drug resistance. In:. C Kuiken, Foley, B, Hahn, B, Marx, P, McCutchan, F, Mellors, J, Mullins, J, Wolinsky, S, Korber, B. HIV sequence compendium 2000. Los Alamos National Laboratory: Theoretical Biology and Biophysics Group; 2000. p. 106–61.
   Google Scholar
• Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66: 3183–7
   PubMed Web of Science ®Google Scholar
• Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Mullins JJ. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73: 10489–502
   PubMed Web of Science ®Google Scholar
• Philpott S, Weiser B, Anastos K, Kitchen CMR, Robison E, Meyer III WA, et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Investig 2001; 107: 431–8
   PubMed Web of Science ®Google Scholar
• Kitchen CMR, Philpott S, Burger H, Weiser B, Anastos K, Suchard MA. Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral therapy: a Bayesian approach. J Virol 2004; 78: 11296–302
   PubMed Web of Science ®Google Scholar
• Deeks SG, Wrin T, Liegler T, et al. Virological and immunological consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viraemia. New Engl J Med 2001; 344: 472–80
   PubMed Web of Science ®Google Scholar